Almost 2.5 million consumers signed up for health insurance through December 15 as part of open enrollment, and 48% were new consumers.
Almost 2.5 million consumers signed up for health insurance through December 15 as part of open enrollment, and 48% were new customers, according to the Department of Health and Human Services (HHS).
HHS has said it expects 9.1 million to 9.9 million total enrolments by the end of 2015.
Healthcare.gov logged 10.8 million users during that timeframe while the call center handled almost 4.1 million calls, according to HHS data. There were also 348,000 visitors to CuidadoDeSalud.gov, and 361,000 calls with Spanish-speaking representatives.
Few problems were reported with the web site or the call centers, a stark contrast to last year’s disastrous launch of the state and federally-facilitated exchanges.
READ: HHS-OIG leads probe into healthcare.gov hacking
“I am pleased with the response to date on Open Enrollment, but we know we still have a lot of work to do between now and February 15,” said HHS Secretary Sylvia Burwell. “People were ready to get covered and the vast majority are having a good consumer experience.”
New for the current open enrollment period is a window shopping feature which lets healthvcare.gov visitors browse health insurance plans without commitment. Almost 4.1 million visitors took advantage of the window shopping tool from October through December 15, according to HHS.
FDA Issues Complete Response Letter for Pz-Cel to Treat Epidermolysis Bullosa
April 22nd 2024Prademagene zamikeracel is a cell therapy designed to incorporate the functional collagen-producing COL7A1 gene into a patient’s own skin cells. The FDA is asking for additional information on manufacturing practices.
Read More
In this episode of the "Meet the Board" podcast series, Briana Contreras, Managed Healthcare Executive editor, speaks with Ateev Mehrotra, a member of the MHE editorial advisory board and a professor of healthcare policy and medicine at Harvard Medical School. Mehtrotra is also a hospitalist at the Beth Israel Deaconess Medical Center in Boston. In the discussion, Contreras gets to know Mehrotra more on a personal level and picks his brain on some of his research interests including telehealth, alternative payment models and price transparency.
Listen
FDA Approves Stelara Biosimilar, Selarsdi
April 18th 2024Alvotech’s Selarsdi (ustekinumab-aekn), a biosimilar referencing Stelara (ustekinumab), gained FDA approval, making it the second ustekinumab biosimilar and second for the company to be given the green light for the American market.
Read More
Eric Levin talks PBMs and how Scripta is Tackling the Market's Challenges for Patients
July 22nd 2020MHE's Briana Contreras spoke with CEO of Scripta, Eric Levin. The two discussed the current state of the pharmacy benefit market and how the Scripta organization has been assisting its clients and their prescriptions prior to the COVID-19 pandemic and during.
Listen
Drugs to Watch: Mental Health Conditions
April 11th 2024The FDA is reviewing two novel therapies: a psychedelic-assisted therapy for PTSD with a target action date of Aug. 11, 2024, and therapy for schizophrenia that does not directly block dopamine receptors with an action date of Sept. 26, 2024.
Read More